A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 870
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : EETs
Long Form : epoxyeicosatrienoic acids
No. Year Title Co-occurring Abbreviation
2020 A COX-2/sEH dual inhibitor PTUPB alleviates lipopolysaccharide-induced acute lung injury in mice by inhibiting NLRP3 inflammasome activation. ALI, ARA, COX-2, LPS, NLRP3, sEH
2020 A COX-2/sEH dual inhibitor PTUPB ameliorates cecal ligation and puncture-induced sepsis in mice via anti-inflammation and anti-oxidative stress. CLP, COX-2, sEH
2020 Apelin inhibits an endothelium-derived hyperpolarizing factor-like pathway in rat cerebral arteries. EDHF, NO
2020 Assessment of the Effect of Sorafenib on Omega-6 and Omega-3 Epoxyeicosanoid Formation in Patients with Hepatocellular Carcinoma. 19,20-EDP, AA, DHA, HCC, PUFAs, sEH
2020 Biosynthesis and immunity of epoxyeicosatrienoic acids in a lepidopteran insect, Spodoptera exigua. EPX, RNAi
2020 Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. SHR
2020 Complex interrelationships between nitro-alkene-dependent inhibition of soluble epoxide hydrolase, inflammation and tumor growth. DHET, KI, sEH, WT
2020 CYP2J2-produced epoxyeicosatrienoic acids attenuate ischemia/reperfusion-induced acute kidney injury by activating the SIRT1-FoxO3a pathway. I/R
2020 Cytochrome 450 metabolites of arachidonic acid (20-HETE, 11,12-EET and 14,15-EET) promote pheochromocytoma cell growth and tumor associated angiogenesis. 20-HETE, AA, MPC
10  2020 Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases. AD, ARA, EpFAs, PD, sEH
11  2020 Cytochrome P450 epoxygenase-derived 5,6-epoxyeicosatrienoic acid relaxes pulmonary arteries in normoxia but promotes sustained pulmonary vasoconstriction in hypoxia. HPV, IPAs, PASMCs
12  2020 Eicosanoid blood vessel regulation in physiological and pathological states. 11,12,15-THETA, 12S-HETE, COX, EDHF, ET-1, LO, PGI2
13  2020 Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. ---
14  2020 Epoxyeicosatrienoic acid prevents maladaptive remodeling in pressure overload by targeting calcineurin/NFAT and Smad-7. TAC
15  2020 Epoxyeicosatrienoic acids inhibit the activation of NLRP3 inflammasome in murine macrophages. ALI, ATP, LPS, NLRP3, ROS, sEH
16  2020 Epoxyeicosatrienoic acids: Emerging therapeutic agents for central post-stroke pain. CPSP
17  2020 Evidence for wall shear stress-dependent t-PA release in human conduit arteries: role of endothelial factors and impact of high blood pressure. tPA
18  2020 Higher Epoxyeicosatrienoic Acids in Cardiomyocytes-Specific CYP2J2 Transgenic Mice Are Associated with Improved Myocardial Remodeling. CYP2J2, MI, ROS, TR, WT
19  2020 Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? ARDS, sEH, SPMs
20  2020 Inhibition of soluble epoxide hydrolase attenuates renal tubular mitochondrial dysfunction and ER stress by restoring autophagic flux in diabetic nephropathy. DN, EpFAs, ER, ESRD, HG, ROS, sEH
21  2020 Nax-positive glial cells in the organum vasculosum laminae terminalis produce epoxyeicosatrienoic acids to induce water intake in response to increases in [Na+] in body fluids. Nax-KO, OVLT, sCVOs, WT
22  2020 Neuroinflammation is able to downregulate cytochrome P450 epoxygenases 2J3 and 2C11 in the rat brain. AA
23  2020 Peripheral soluble epoxide hydrolase inhibition reduces hypernociception and inflammation in albumin-induced arthritis in temporomandibular joint of rats. RA, sEH, TMJ, TPPU
24  2020 Peroxisome proliferator-activated receptor ɑ (PPARɑ)-cytochrome P450 epoxygenases-soluble epoxide hydrolase axis in ER + PR + HER2- breast cancer. PPARalpha, sEH
25  2020 PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP. AD, PD, PET, sEH, VCI
26  2020 Role of epoxyeicosatrienoic acids in the lung. ---
27  2020 Soluble epoxide hydrolase inhibition improves cognitive function and parenchymal artery dilation in a hypertensive model of chronic cerebral hypoperfusion. BCAS, CCH, PAs, sEH, SHSRP
28  2020 The contribution of chymase-dependent formation of ANG II to cardiac dysfunction in metabolic syndrome of young rats: roles of fructose and EETs. ACE, AT1R, HFD, MetS, NO, NOX, sEH, TPPU
29  2020 The interaction Between Arachidonic Acid Metabolism and Homocysteine. AA, CVD, Hcy, HETEs, HHcy, PGs, TXA
30  2020 Time-resolved phosphoproteomic analysis elucidates hepatic 11,12-Epoxyeicosatrienoic acid signaling pathways. ---
31  2020 ZDHXB-101 (3',5-Diallyl-2, 4'-dihydroxy-[1,1'-biphen-yl]-3,5'-dicarbaldehyde) protects against airway remodeling and hyperresponsiveness via inhibiting both the activation of the mitogen-activated protein kinase and the signal transducer and activator of transcription-3 signaling pathways. AHR, CYP, IL, JNK, sEH, STAT3
32  2019 11,12 and 14,15 epoxyeicosatrienoic acid rescue deteriorated wound healing in ischemia. MMP, SD, TIMP
33  2019 Activation of vitamin D receptor attenuates high glucose-induced cellular injury partially dependent on CYP2J5 in murine renal tubule epithelial cell. DN, LDH, STZ, VDR
34  2019 Alleviation of Mechanical Allodynia by 14,15-Epoxyeicosatrienoic Acid in a Central Poststroke Pain Model: Possible Role of Allopregnanolone and delta-Subunit-Containing Gamma-Aminobutyric Acid A Receptors. AP, CPSP, deltaGABAAR
35  2019 Altered bioavailability of epoxyeicosatrienoic acids is associated with conduit artery endothelial dysfunction in type 2 diabetic patients. DHETs, sEH
36  2019 Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure. ACF, ACh, Ang II, BK, CHF, NE, RBF, TGRs
37  2019 Arachidonic Acid Metabolism and Kidney Inflammation. 19-HETE, AA, COX, CYP450, HETEs, LOX, LTB4, LTs, PG, PGs, TX
38  2019 Circadian Variation in Vasoconstriction and Vasodilation Mediators and Baroreflex Sensitivity in Hypertensive Rats. 1K-1C AH, BP, CGRP, CHI, ET-1, HP, SO
39  2019 CYP2C11 played a significant role in down-regulating rat blood pressure under the challenge of a high-salt diet. AA, WT
40  2019 EETs/PPARs activation together mediates the preventive effect of naringenin in high glucose-induced cardiomyocyte hypertrophy. ANF, PPARs
41  2019 Eicosanoid Profile of Influenza A Virus Infected Pigs. HDHAs, HETEs, IAV
42  2019 Endothelium-dependent adaptation of arterial wall viscosity during blood flow increase is impaired in essential hypertension. AWV, HT, NT
43  2019 Enzymatic Synthesis of Epoxidized Metabolites of Docosahexaenoic, Eicosapentaenoic, and Arachidonic Acids. AA, EDPs, EPA, HPLC, MS, NMR, PUFAs, sEH
44  2019 Epoxyeicosanoids in hypertension. sEH
45  2019 Epoxyeicosatrienoic acid (EET)-stimulated angiogenesis is mediated by epoxy hydroxyeicosatrienoic acids (EHETs) formed from COX-2. 8,9,11-EHET, COX-2, EET, EHETs, HAECs, PDBu, VEGF
46  2019 Epoxyeicosatrienoic Acid Analog EET-A Blunts Development of Lupus Nephritis in Mice. CXCR, SLE
47  2019 Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. ECHO, FS, HO-1, MI, SBP, SHR
48  2019 Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats. FS, HanSD, HF, LAD, LV, MI, TGR
49  2019 Epoxyeicosatrienoic acids alleviate methionine-choline-deficient diet-induced non-alcoholic steatohepatitis in mice. FFA, MCD, NASH, PPAR-alpha, SREBP-1c
50  2019 Epoxyeicosatrienoic acids protect pancreatic beta cells against pro-inflammatory cytokine toxicity. DM
51  2019 Expression, purification, and characterisation of human soluble Epoxide Hydrolase (hsEH) and of its functional C-terminal domain. hsEH
52  2019 Increased Soluble Epoxide Hydrolase in Human Gestational Tissues from Pregnancies Complicated by Acute Chorioamnionitis. AUDA, CAM, DHETs, LPS, sEH
53  2019 Inhibition of soluble epoxide hydrolase ameliorates hyperhomocysteinemia-induced hepatic steatosis by enhancing beta-oxidation of fatty acid in mice. HHcy, PPAR-alpha, sEH
54  2019 Inhibition of soluble epoxide hydrolase attenuates a high-fat diet-mediated renal injury by activating PAX2 and AMPK. CMA, DHETs, HFD, mRMCs, PA, sEH
55  2019 Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer. METABRIC, TNBC
56  2019 Nox4 and soluble epoxide hydrolase synergistically mediate homocysteine-induced inflammation in vascular smooth muscle cells. ROS, sEH, VSMC
57  2019 Obesity in Aging Exacerbates Neuroinflammation, Dysregulating Synaptic Function-Related Genes and Altering Eicosanoid Synthesis in the Mouse Hippocampus: Potential Role in Impaired Synaptic Plasticity and Cognitive Decline. LTP
58  2019 Pharmaceutical Effects of Inhibiting the Soluble Epoxide Hydrolase in Canine Osteoarthritis. OA, PGs, PUFAs, sEH, sEHI
59  2019 Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats. ACF, CHF, CKD, FHH, FHL, sEH
60  2019 Polymorphisms in vasoactive eicosanoid genes of kidney donors affect biopsy scores and clinical outcomes in renal transplantation. 20-HETE, eGFR
61  2019 PPARalpha ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis. 11-HETE, AA, COX, ERK, LC, PPARalpha
62  2019 Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease. CMap, EPHX2i
63  2019 Reciprocal actions of constrictor prostanoids and superoxide in chronic hypoxia-induced pulmonary hypertension: roles of EETs. ET, HPH, PAAT, RVSP, sEH, sEH-KO, TXA2, VTI, WT
64  2019 Role of cytochrome epoxygenase (CYP2J2) in the pathophysiology of coronary artery disease in South Indian population. CAD, CYP2J2, LDL-C, PCR, TC, TC/HDL
65  2019 Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy. CYP2J, DHETs, sEH
66  2019 Role of epoxy-fatty acids and epoxide hydrolases in the pathology of neuro-inflammation. sEH
67  2019 Role of NF-kappaB in cytochrome P450 epoxygenases down-regulation during an inflammatory process in astrocytes. EMSA
68  2019 sEH Inhibitor TPPU Ameliorates Cecal Ligation and Puncture-Induced Sepsis by Regulating Macrophage Functions. CLP, DHETs, sEH
69  2019 Soluble epoxide hydrolase inhibitor, APAU, protects dopaminergic neurons against rotenone induced neurotoxicity: Implications for Parkinson's disease. PD, ROT, sEH
70  2019 Soluble Epoxide Hydrolase Inhibitor: A Novel Potential Therapeutic or Prophylactic Drug for Psychiatric Disorders. EDPs, sEH
71  2019 TPPU, a sEH Inhibitor, Attenuates Corticosterone-Induced PC12 Cell Injury by Modulation of BDNF-TrkB Pathway. CORT, sEH
72  2019 Vascular repair and anti-inflammatory effects of soluble epoxide hydrolase inhibitor. AUDA, HCAECs, IL, IVIG, KD, MMP, sEH, TNF
73  2018 14,15-epoxyeicosatrienoic acid produced by cytochrome P450s enhances neurite outgrowth of PC12 and rat hippocampal neuronal cells. HETEs, TRP
74  2018 Ablation of soluble epoxide hydrolase reprogram white fat to beige-like fat through an increase in mitochondrial integrity, HO-1-adiponectin in vitro and in vivo. HO-1, sEH
75  2018 Alteration in the availability of epoxyeicosatrienoic acids contributes with NO to the development of endothelial dysfunction in conduit arteries during aging. ---
76  2018 Arachidonic acid in health and disease with focus on hypertension and diabetes mellitus: A review. COX, LOX, LXA4
77  2018 Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. CKD, RAS, sEH, TGR
78  2018 CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity. AA, CYP2J2, ROS
79  2018 CYP2J2-derived EETs attenuated ethanol-induced myocardial dysfunction through inducing autophagy and reducing apoptosis. ---
80  2018 Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity. AA, CYP2J2
81  2018 Deletion of soluble epoxide hydrolase attenuates mice Hyperoxic acute lung injury. Keap1, Nrf2, sEH, WT
82  2018 Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis. AUDA-BE, DHETs, MD, MM/PBSA, sEH
83  2018 Dronedarone-Induced Cardiac Mitochondrial Dysfunction and Its Mitigation by Epoxyeicosatrienoic Acids. AA, ETC, NDBD, NDEA
84  2018 Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula. ACF, CHF, RAS, sEH, TGR
85  2018 Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation. HFD, NAFLD, NF-kB, OCA
86  2018 Eicosanoids via CYP450 and cardiovascular disease: Hints from genetic and nutrition studies. 20-HETE, GWAS, SNPs
87  2018 Endothelium-specific CYP2J2 overexpression attenuates age-related insulin resistance. ---
88  2018 Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia. DHETs, EPHX1, EPHX2, WT
89  2018 Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner. PPARalpha, sEH
90  2018 Expression of soluble epoxide hydrolase in renal tubular epithelial cells regulates macrophage infiltration and polarization in IgA nephropathy. sEH
91  2018 Genetic deletion of 12/15 lipoxygenase promotes effective resolution of inflammation following myocardial infarction. HO, LOX, MI, SMA, WT
92  2018 Heart failure-induced activation of phospholipase iPLA2gamma generates hydroxyeicosatetraenoic acids opening the mitochondrial permeability transition pore. AA, cPLA2zeta, HETEs, mPTP
93  2018 Increased epoxyeicosatrienoic acids may be part of a protective mechanism in human ulcerative colitis, with increased CYP2J2 and reduced soluble epoxide hydrolase expression. sEH
94  2018 Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1alpha via downregulation of prolyl hydroxylase 3. HIF, PHD3
95  2018 Inhibition of Soluble Epoxide Hydrolase 2 Ameliorates Diabetic Keratopathy and Impaired Wound Healing in Mouse Corneas. HO-1, sEH, STZ
96  2018 Inhibition of soluble epoxide hydrolase attenuates eosinophil recruitment and food allergen-induced gastrointestinal inflammation. GI, sEH, SPI
97  2018 Neuroprotective effects of epoxyeicosatrienoic acids. sEH
98  2018 Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. sEH
99  2018 Ophiopogonin D Reduces Myocardial Ischemia-Reperfusion Injury via Upregulating CYP2J3/EETs in Rats. MI/R, OP-D, SMI
100  2018 Oxidative Stress and Renal Fibrosis: Recent Insights for the Development of Novel Therapeutic Strategies. cGMP-cGK1-PDE, CKD, Cygb, NADPH, NO, Nrf2, PPARgamma, TGF-beta1